Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis Candida parapsilosis : Analysis of pooled data from six prospective clinical studies

摘要

Summary Concerns with echinocandin use for infections caused by Candida parapsilosis complex species have driven the need for data to support echinocandin clinical efficacy in such patients. Data from six prospective studies were pooled to assess efficacy and safety of anidulafungin in patients with candidaemia caused by C.?parapsilosis . Patient‐level data were pooled from patients with microbiologically confirmed candidaemia due to C.?parapsilosis treated with anidulafungin. Patients received a 200?mg intravenous ( IV ) loading dose of anidulafungin (day 1) and 100?mg daily thereafter. IV treatment could be switched to oral azole therapy after ≥5 or ≥10?days. Primary endpoint was global response at end of IV therapy ( EOIVT ). Seventy patients had candidaemia caused by C.?parapsilosis . Global response was 77.1% (95% CI : 67.3, 87.0) at EOIVT and 70.0% (95% CI : 59.3, 80.7) at end of treatment. Three of 55 isolates (with MIC s available) were resistant to anidulafungin ( MIC ≥8?mg/L). All‐cause mortality was 5.7% (n=4/70) by day 14 and 14.3% (n=10/70) by day 28. IV anidulafungin was effective for the treatment of C.?parapsilosis candidaemia in this population, consistent with efficacy previously demonstrated for other Candida species. (ClinicalTrials.gov identifiers: NCT 00496197, NCT 00548262, NCT 00537329, NCT 00689338, NCT 00806351, NCT 00805740).